TY - JOUR
T1 - The phosphoinositide 3-kinase/Akt1/Par-4 axis
T2 - A cancer-selective therapeutic target
AU - Goswami, Anindya
AU - Ranganathan, Padhma
AU - Rangnekar, Vivek M.
PY - 2006/3/15
Y1 - 2006/3/15
N2 - Activation of the phosphoinositide 3-kinase (PI3K)/Akt cell survival pathway in many cancers makes it an appealing target for therapeutic development. However, because this pathway also has an important role in the survival of normal cells, tactics to achieve cancer selectivity may prove important. We recently showed that the cancer-selective proapoptotic protein Par-4 is a key target for inactivation by PI3K/Akt signaling. Additionally, we found that Par-4 participates in mediating apoptosis by PTEN, the tumor suppressor responsible for blocking PI3K/Akt signaling. As a central player in cancer cell survival, Par-4 may provide a useful focus for the development of cancer-selective therapeutics.
AB - Activation of the phosphoinositide 3-kinase (PI3K)/Akt cell survival pathway in many cancers makes it an appealing target for therapeutic development. However, because this pathway also has an important role in the survival of normal cells, tactics to achieve cancer selectivity may prove important. We recently showed that the cancer-selective proapoptotic protein Par-4 is a key target for inactivation by PI3K/Akt signaling. Additionally, we found that Par-4 participates in mediating apoptosis by PTEN, the tumor suppressor responsible for blocking PI3K/Akt signaling. As a central player in cancer cell survival, Par-4 may provide a useful focus for the development of cancer-selective therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=33645524134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645524134&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-4458
DO - 10.1158/0008-5472.CAN-05-4458
M3 - Review article
C2 - 16540633
AN - SCOPUS:33645524134
SN - 0008-5472
VL - 66
SP - 2889
EP - 2892
JO - Cancer Research
JF - Cancer Research
IS - 6
ER -